PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2014; 35(02): 176-180
DOI: 10.4103/0971-5851.138997
CONFERENCE REVIEW

American Society of Clinical Oncology 2014: Updates in breast and gastrointestinal cancers

Shaheenah Dawood
Department of Medical Oncology, Dubai Hospital, Dubai, UAE
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  als PDF herunterladen Lizenzen und Reprints

Abstract

The last two decades have been very exciting in the realm of breast and GI oncology with a plethora of new information that has significantly impacted clinical practice. From the use of anti HER 2 agents in both the adjuvant and metastatic settings of breast cancer to the use of anti EGFR agents in the metastatic setting of colorectal cancer we have seen some significant advances in the treatment of these diseases. This year at ASCO 2014 data were presented that attempted to answer important clinical questions faced by a community oncologist in the clinic. This review focuses on important data presented for both breast and GI cancer.

Keywords

Breast cancer - colon cancer - gastric cancer


Publikationsverlauf

Artikel online veröffentlicht:
19. Juli 2021

© 2014. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Moebus VJ, Von Minckwitz G, Jackisch C, Lueck HJ, Schneeweiss A, Tesch H, et al. German Adjuvant Intergroup Node Positive (GAIN) study: A phase III trial to compare IDD-ETC versus EC-TX in patients with node-positive primary breast cancer - Final efficacy analysis. J Clin Oncol 2014;32:5s. [Suppl; abst].
  • 2 Janni W, Schneeweiss A, Haeberle L, Fasching PA, Sommer HL, Rezai M, et al. Adjuvant gemcitabine for high-risk breast cancer (BC) patients: Final survival results of the randomized phase III SUCCESS - A study. J Clin Oncol 2014;32:5s. [Suppl; abstr 1010].
  • 3 Piccart-Gebhart MJ, Holmes AP, Baselga J, De Azambuja E, Dueck AC, Viale G, et al. First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T + L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). J Clin Oncol 2014;32:5s. [Suppl; abstr LBA4].
  • 4 Pagani O, Regan MM, Walley B, Fleming GF, Colleoni M, Lang I, et al. Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol 2014;32:5s. [Suppl; abstr LBA1].
  • 5 Pan H, Gray RG. On Behalf of the Early Breast Cancer Trialists′ Collaborative Group; Effect of obesity in premenopausal ER + early breast cancer: EBCTCG data on 80,000 patients in 70 trials. J Clin Oncol 2014;32:5s. [Suppl; abstr 503].
  • 6 Lohmann AE, Chapman JA, Margot J, et al. Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). J Clin Oncol 2014;32:5s. [Suppl; abstr 504].
  • 7 Hong YS, Nam BH, Kim KP, Lee JL, Park JO, Park YS, et al. Adjuvant chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) versus 5-fluorouracil/leucovorin (FL) for rectal cancer patients whose postoperative yp stage 2 or 3 after preoperative chemoradiotherapy: Updated results of 3-year disease-free survival from a randomized phase II study (The ADORE). J Clin Oncol 2014;32:5s. [Suppl; abstr 3502].
  • 8 Rodel C, Liersch T, Fietkau R, Hohenberger W, Graeven U, Hothorn T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: Results of the German CAO/ARO/AIO-04 randomized phase III trial. J Clin Oncol 2014;32:5s. [Suppl; abstr 3500].
  • 9 Tougeron D, Sickersen G, Lecomte T, Mouillet G, Trouilloud I, Coriat R, et al. Impact of adjuvant chemotherapy with 5-FU or FOLFOX in colon cancers with microsatellite instability: An AGEO multicenter study. J Clin Oncol 2014;32:5s. [suppl; abstr 3508].
  • 10 Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Mahoney MR, O′Neil BH, et al. Cancer and Leukemia Group B (Alliance), SWOG, and ECOG; CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014;32:5s. [Suppl; abstr LBA3].
  • 11 Arnold D, Graeven U, Lerchenmuller CA, Killing B, Depenbusch R, Steffens CC, et al. Maintenance strategy with fluoropyrimidines (FP) plus Bevacizumab (Bev), Bev alone, or no treatment, following a standard combination of FP, oxaliplatin (Ox), and Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC): A phase III non-inferiority trial (AIO KRK 0207). J Clin Oncol 2014;32:5s. [Suppl; abstr 3503^].
  • 12 Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32:5s. [Suppl; abstr 3509].
  • 13 Dienstmann R, Guinney J, Delorenzi M, Reynies AD, Roepman P, Sadanandam A, et al. Colorectal Cancer Subtyping Consortium; Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes. J Clin Oncol 2014;32:5s. [Suppl; abstr 3511].
  • 14 Hironaka S, Shimada Y, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, et al. RAINBOW: A global, phase III, randomized, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of metastatic gastroesophageal junction and gastric adenocarcinoma (mGC) following disease progression on first-line platinum-and fluoropyrimidine-containing combination therapy-Efficacy analysis in Japanese and Western patients. J Clin Oncol 2014;32:5s. [Suppl; abstr 4005].
  • 15 Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip AP, Cohn AL, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. J Clin Oncol 2014;32:5s. [Suppl; abstr 4004].
  • 16 Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, et al. STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). J Clin Oncol 2014;32:5s. [Suppl; abstr 4006].